¼¼°èÀÇ Schmallenberg ¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå
Schmallenberg Virus Treatment
»óǰÄÚµå : 1744865
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 378 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,130,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,390,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Schmallenberg ¹ÙÀÌ·¯½º Ä¡·á ½ÃÀåÀº 2030³â±îÁö 1¾ï 5,770¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 940¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Schmallenberg ¹ÙÀÌ·¯½º Ä¡·á ½ÃÀåÀº 2024-2030³â¿¡ CAGR 6.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 1¾ï 5,770¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®µÇ°í ÀÖ´Â ºÎ¹®ÀÇ ÇϳªÀÎ ¼Ò´Â CAGR 5.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 7,530¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ç ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 8.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 2,980¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÇÑÆí, Áß±¹Àº CAGR 9.7%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Schmallenberg ¹ÙÀÌ·¯½º Ä¡·á ½ÃÀåÀº 2024³â¿¡ 2,980¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 9.7%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 3,200¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.2%¿Í 6.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Schmallenberg ¹ÙÀÌ·¯½º Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼öÀÇÇаè´Â ½´¸»·»º£¸£Å© ¹ÙÀÌ·¯½ºÀÇ Á¶¿ëÇÑ À§Çù¿¡ ¾î¶»°Ô ´ëóÇϰí Àִ°¡?

2011³â À¯·´¿¡¼­ óÀ½ È®ÀÎµÈ ½´¸»·»º£¸£Å© ¹ÙÀÌ·¯½º(SBV)´Â ÁÖ·Î ¼Ò, ¾ç, ¿°¼Ò µî ¹ÝÃßµ¿¹°¿¡ °¨¿°µÇ¾î ¹ß¿­, À¯·®°¨¼Ò, À¯»ê, ¼±Ãµ¼º ±âÇüÀ» À¯¹ßÇÏ´Â ½ÅÈï Àü¿°º´ÀÔ´Ï´Ù. ÀÌ Àü¿°º´ÀÇ È®»êÀº ÁÖ·Î ¹°¸° ¸Ó¸´´Ï(¹®Á¦)¸¦ ¸Å°³·Î Çϴµ¥, ƯÀÌÀûÀÎ Ç×¹ÙÀÌ·¯½º Ä¡·áÁ¦°¡ ¾ø¾î ¼öÀÇ º¸°Ç ½Ã½ºÅÛ¿¡ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ÇöÀç ½ÃÀå °³¹ßÀÇ ÃÊÁ¡Àº ¹é½Å °³¹ß°ú Á¶±â ºÀ¼â¸¦ À§ÇÑ Áø´Ü ÇÁ·ÎÅäÄÝÀ» °­È­ÇÏ´Â µÎ °¡ÁöÀÔ´Ï´Ù. µ¿¹°¿ë Á¦¾à»çµéÀº º¸´Ù ±¤¹üÀ§Çϰí Áö¼ÓÀûÀÎ ¸é¿ªÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ºÒȰȭ ¹é½Å°ú ÀçÁ¶ÇÕ ¹é½ÅÀÇ ¿¬±¸°³¹ßÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. À¯·´, ¾Æ½Ã¾Æ, ³²¹Ì °¢±¹ÀÇ Á¤ºÎ ¹× ¼öÀÇÇÐ ±â°üÀº Áö¿ªÀû SBV °¨½Ã ÇÁ·Î±×·¥, ¹ÙÀÌ¿À º¸¾È ÀÎ½Ä Á¦°í, ±ÔÁ¦ ¿ì´ëÁ¶Ä¡¸¦ ÅëÇÑ ¹é½Å ½ÃÇè ½Å¼ÓÈ­ µîÀÇ ³ë·Â¿¡ ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå È®´ë´Â »ó¾÷Àû °æÀÛÁö¿¡¼­ÀÇ °¡Ãà º¸È£¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Áø´ÜÀÇ ¹ßÀüÀÌ ¹ÙÀÌ·¯½ºÀÇ º¯À̸¦ ´É°¡Çϴ°¡?

°ËÃâ°ú Áø´ÜÀº ½´¸»·»º£¸£±× ¹ßº´À» °ü¸®ÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¿ä¼Ò·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Â÷¼¼´ë PCR ±â¹Ý °Ë»ç, Ç÷ûÇÐÀû ELISA ¹× ÇöÀå Áø´ÜÀÌ °³¹ßµÇ¾î »ì¾ÆÀÖ´Â µ¿¹°°ú ÅÂ¾Æ ¸ðµÎ¿¡¼­ °ËÃâ Á¤È®µµ°¡ Çâ»óµÇ¾ú½À´Ï´Ù. ÈÞ´ë¿ë ºÐÀÚ °Ë»ç ŰƮ´Â ƯÈ÷ ½ÅÈï °æÁ¦±¹¿¡¼­ ¹ø½Ä±â³ª ºÐ¸¸ Àü Áúº´À» È®ÀÎÇϱâ À§ÇØ Áö¹æ µ¿¹°º´¿ø¿¡¼­ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ³¯¾¾, ¸Ó¸´´Ï À̵¿, °¡Ãà À̵¿¿¡ ±â¹ÝÇÑ AI¸¦ Ȱ¿ëÇÑ ¹ß»ý ¿¹Ãø ¸ðµ¨µµ ¼öÀÇÇÐ ÀÇ»ç°áÁ¤ Áö¿ø ½Ã½ºÅÛ¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úµéÀº ºñ¹ß»ý Áö¿ª¿¡¼­ÀÇ ¿¹ÃøÇÒ ¼ö ¾ø´Â ¹ÙÀÌ·¯½º ÀçÀ¯ÇàÀ» ¿ÏÈ­ÇÏ°í ³«³ó ¹× À°·ù »ý»êÀÇ °æÁ¦Àû ¼Õ½ÇÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À º¸¾È Á¤Ã¥°ú ¼¼°è °¡Ãà ¹«¿ªÀÇ ¿ªÇÒÀº ¹«¾ùÀΰ¡?

°¡Ãà ¹«¿ªÀÇ ¼¼°èÈ­¿Í ±âÈÄ·Î ÀÎÇÑ ¸Å°³µ¿¹°ÀÇ È®´ë´Â ±¹°æÀ» ÃÊ¿ùÇÑ SBV ÀüÆÄÀÇ À§ÇèÀ» ³ôÀÌ´Â ¸Å¿ì Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. µû¶ó¼­ Áúº´ ´ëÃ¥¿¡ ´ëÇÑ ±¹°¡ °£ Çù·ÂÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ¼öÃâ ±ÔÁ¦´Â SBV¿¡ °¨¿°µÇÁö ¾ÊÀº °ÍÀ¸·Î ÀÔÁõµÈ ¼Ò¸¦ ¿ä±¸Çϰí ÀÖÀ¸¸ç, ³óÀåÀº ¿¹¹æÁ¢Á¾°ú ¿¹¹æÁø´Ü¿¡ ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. ÇÇÇØ Áö¿ª Á¤ºÎ¿Í ³ó¹«ºÎ´Â °¡Ãà ÃßÀû ½Ã½ºÅÛ ¹× ¹ÙÀÌ¿À º¸¾È ±¸¿ª ¼³Á¤À» Àǹ«È­ÇÏ¿© Áúº´ È®»êÀ» ¹æÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àμö°øÅëÀü¿°º´°ú ½ÅÁ¾ Àü¿°º´¿¡ ´ëÇÑ ÆÒµ¥¹Í ½Ã´ëÀÇ ½ºÆ÷Æ®¶óÀÌÆ®´Â ¼öÀÇÇÐ ÀÎÇÁ¶ó¿¡ ´ëÇÑ Àνİú ÀÚ±ÝÀ» Áõ°¡½ÃÄÑ SBV Ä¡·á ½ÃÀå¿¡ °£Á¢ÀûÀÎ ÀÌÀÍÀ» °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. °¡Ãà º¸Çè»ç ¹× ³ó»ê¾÷ ÀÌÇØ°ü°èÀڵ鵵 Ã¥ÀÓÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ¹é½Å äÅÃÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù.

Schmallenberg ¹ÙÀÌ·¯½º Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÃËÁøµË´Ï´Ù.

¹é½Å°ú °í°¨µµ Áø´ÜŰƮ µî ¿¹¹æÃ¥ÀÌ °­Á¶µÇ°í ÀÖ´Â °¡¿îµ¥ °áÁ¤ÀûÀÎ Ä¡·á¹ýÀÌ ¾ø½À´Ï´Ù´Â Á¡ÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ À¯·´°ú ¶óƾ¾Æ¸Þ¸®Ä«¿¡¼­´Â »ó¾÷Àû Ãà»ê¾÷ÀÌ È®´ëµÇ°í °¡Ãà Áúº´¿¡ ´ëÇÑ °æÁ¦Àû ºÎ´ãÀÌ Ä¿Áö¸é¼­ È¿°úÀûÀÎ SBV ´ëÃ¥¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿¹°¿ë ¹é½Å °³¹ß¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú ½Å¼ÓÇÑ ½ÂÀÎÀº »ý¸í°øÇÐ ±â¾÷ÀÌ SBV¿¡ ƯȭµÈ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±âÈÄ ÆÐÅÏÀÇ º¯È­·Î ÀÎÇØ ÀÌ Áúº´ÀÇ Áö¿ªÀû ¹üÀ§°¡ È®´ëµÇ¾î Ä¡·á¿Í ¹æÁ¦¸¦ À§ÇÑ »õ·Î¿î ½ÃÀåÀÌ Ã¢ÃâµÇ°í ÀÖ½À´Ï´Ù. ÅëÇÕ °¡Ãà °ü¸® Ç÷§ÆûÀÇ ºÎ»ó, ¼öÀÇÇÐ ¿¹»ê Áõ°¡, µðÁöÅÐ Áúº´ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀº ½´¸»·»¹ö±× ¹ÙÀÌ·¯½º Ä¡·á ¼Ö·ç¼ÇÀÇ ±ä±Þ¼º°ú »ó¾÷Àû ½ÇÇà °¡´É¼ºÀ» ÃÑüÀûÀ¸·Î °­È­Çϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

µ¿¹° À¯Çü(¼Ò, ¾ç, ¿°¼Ò, ±âŸ µ¿¹° À¯Çü); Ä¡·á À¯Çü(Ç×¹ÙÀÌ·¯½ºÁ¦, Ç׿°Áõ¾à, ÁøÅëÁ¦, ¹é½Å); ÃÖÁ¾»ç¿ëÀÚ(µ¿¹°º´¿ø & Ŭ¸®´Ð, Á¶»ç±â°ü, µ¿¹° ¾à±¹ & µå·¯±×½ºÅä¾î, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 36°Ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ < gt; Áß±¹ < gt; ¸ß½ÃÄÚ < gt; ij³ª´Ù < gt; EU < gt; ÀϺ» < gt; Àεµ < gt; ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Schmallenberg Virus Treatment Market to Reach US$157.7 Million by 2030

The global market for Schmallenberg Virus Treatment estimated at US$109.4 Million in the year 2024, is expected to reach US$157.7 Million by 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Cattle, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$75.3 Million by the end of the analysis period. Growth in the Sheep segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$29.8 Million While China is Forecast to Grow at 9.7% CAGR

The Schmallenberg Virus Treatment market in the U.S. is estimated at US$29.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.0 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Schmallenberg Virus Treatment Market - Key Trends & Drivers Summarized

How Is the Veterinary Sector Tackling the Silent Threat of Schmallenberg Virus?

First identified in Europe in 2011, Schmallenberg virus (SBV) is an emerging infectious disease that primarily affects ruminants-such as cattle, sheep, and goats-causing fever, reduced milk yield, abortions, and congenital deformities. While its spread is largely vector-borne via biting midges (Culicoides spp.), the lack of specific antiviral treatments has posed a challenge to veterinary health systems. The current focus in the market is twofold: developing vaccines and enhancing diagnostic protocols for early containment. Veterinary pharmaceutical firms are intensifying R&D on inactivated and recombinant vaccines that can provide broader and longer-lasting immunity. Governments and veterinary bodies across Europe, Asia, and South America are funding initiatives for regional SBV surveillance programs, biosecurity awareness, and fast-tracking vaccine trials through regulatory incentives. The market’s expansion is also aided by increasing demand for livestock protection in commercial farming zones.

Are Diagnostic Advancements Outpacing Viral Mutations?

Detection and diagnostics have emerged as crucial pillars in managing Schmallenberg outbreaks. New-generation PCR-based tests, serological ELISAs, and point-of-care diagnostics are being developed to improve detection accuracy in both live animals and fetuses. Portable molecular testing kits are seeing demand in rural veterinary clinics, especially in developing economies, to identify the disease before breeding or calving seasons. AI-powered outbreak prediction models based on weather, midge migration, and livestock movement are also being integrated into veterinary decision-support systems. These technologies are helping mitigate the unpredictable re-emergence of the virus in non-endemic areas, thus reducing economic losses in dairy and meat production.

What Role Do Biosecurity Policies and Global Livestock Trade Play?

The globalization of livestock trade and climate-driven vector expansion are pivotal factors increasing the risk of SBV transmission across borders. As such, cross-country coordination on disease control is becoming more vital. Export regulations now increasingly demand certified SBV-free herds, driving farms to invest in immunization and preventive diagnostics. Governments and agricultural ministries in affected regions have rolled out mandatory livestock tracking systems and biosecurity zoning to limit disease spread. Furthermore, the pandemic-era spotlight on zoonotic and emerging diseases has heightened awareness and funding for veterinary health infrastructure, indirectly benefiting the SBV treatment market. Herd insurance firms and agribusiness stakeholders are also pushing for vaccine adoption to minimize liability.

The Growth in the Schmallenberg Virus Treatment Market Is Driven by Several Factors

The market growth is propelled by the absence of a definitive cure, which emphasizes preventive measures such as vaccines and high-sensitivity diagnostic kits. Expansion of commercial livestock farming, especially in Europe and Latin America, has raised the financial stakes of livestock diseases, increasing demand for effective SBV countermeasures. Regulatory support for veterinary vaccine development and fast-track approvals are encouraging biotech companies to invest in SBV-specific R&D. Changing climate patterns are expanding the geographic range of the disease, creating new markets for treatment and control. The rise of integrated livestock management platforms, increased veterinary healthcare budgets, and digital disease monitoring systems are collectively reinforcing the urgency and commercial viability of Schmallenberg virus treatment solutions.

SCOPE OF STUDY:

The report analyzes the Schmallenberg Virus Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Animal Type (Cattle, Sheep, Goats, Other Animal Types); Treatment Type (Antiviral Drugs, Anti-Inflammatory Drugs, Analgesics, Vaccines); End-Use (Veterinary Hospitals & Clinics, Research Institutions, Veterinary Pharmacies & Drug Store, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â